     |
News & Events
Synapse BioMedical Completes Series C Private Equity Financing Investors provide $4 million in capital to fund further clinical development of novel medical device Cleveland, OH, January 16, 2007– Synapse BioMedical, Inc. today announced the completion of a Series C financing in the amount of $4 million. Synapse is a medical device company developing proprietary products for the treatment of spinal cord injury and Amytrophic Lateral Sclerosis (ALS). The investor syndicate was led by Vivo Ventures with participation from other current Synapse BioMedical investors. Anthony Ignagni, President & CEO stated, “We are pleased to be able to add the substantial and proven resources and capabilities of Vivo Ventures to our investor group. We are excited to leverage this financing to move forward in developing our lead products.” About Synapse BioMedicalSynapse BioMedical is a startup company dedicated to developing, manufacturing, selling and supporting life changing minimally invasive neurostimulation devices used in the diagnosis and treatment of persons with neurological impairment. To learn more about Synapse, visit www.synapsebiomedical.com.
|
About Vivo
At Vivo Ventures, we leverage our internal expertise in evaluating data to generate outsized returns for company founders and employees as well as for our investors. Vivo prides itself on its working relationships with its founders who have often continued to work with the firm in other startup ventures. The majority of Vivo's investments are in U.S. based companies with therapeutic products in clinical development. MORE |